1. Home
  2. VTRS vs CELH Comparison

VTRS vs CELH Comparison

Compare VTRS & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • CELH
  • Stock Information
  • Founded
  • VTRS 1961
  • CELH 2004
  • Country
  • VTRS United States
  • CELH United States
  • Employees
  • VTRS N/A
  • CELH N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • CELH Beverages (Production/Distribution)
  • Sector
  • VTRS Health Care
  • CELH Consumer Staples
  • Exchange
  • VTRS Nasdaq
  • CELH Nasdaq
  • Market Cap
  • VTRS 11.1B
  • CELH 12.0B
  • IPO Year
  • VTRS N/A
  • CELH N/A
  • Fundamental
  • Price
  • VTRS $10.19
  • CELH $58.70
  • Analyst Decision
  • VTRS Hold
  • CELH Strong Buy
  • Analyst Count
  • VTRS 5
  • CELH 18
  • Target Price
  • VTRS $10.40
  • CELH $61.78
  • AVG Volume (30 Days)
  • VTRS 11.7M
  • CELH 5.7M
  • Earning Date
  • VTRS 11-06-2025
  • CELH 11-05-2025
  • Dividend Yield
  • VTRS 4.71%
  • CELH N/A
  • EPS Growth
  • VTRS N/A
  • CELH N/A
  • EPS
  • VTRS N/A
  • CELH 0.39
  • Revenue
  • VTRS $14,115,700,000.00
  • CELH $1,666,480,000.00
  • Revenue This Year
  • VTRS N/A
  • CELH $81.02
  • Revenue Next Year
  • VTRS $1.69
  • CELH $29.95
  • P/E Ratio
  • VTRS N/A
  • CELH $148.73
  • Revenue Growth
  • VTRS N/A
  • CELH 11.85
  • 52 Week Low
  • VTRS $6.85
  • CELH $21.10
  • 52 Week High
  • VTRS $13.55
  • CELH $63.50
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 57.64
  • CELH 59.84
  • Support Level
  • VTRS $9.47
  • CELH $56.20
  • Resistance Level
  • VTRS $10.09
  • CELH $58.90
  • Average True Range (ATR)
  • VTRS 0.25
  • CELH 2.04
  • MACD
  • VTRS 0.04
  • CELH 0.41
  • Stochastic Oscillator
  • VTRS 80.21
  • CELH 79.32

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About CELH Celsius Holdings Inc.

Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), Celsius On-the-Go powder packets, and the recently acquired portfolio of Alani Nu energy drinks and snacks. Celsius dedicates its efforts to branding and innovation, while it largely utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.

Share on Social Networks: